<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20201128049511N6</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2024-01-16</date_registration>
      <primary_sponsor>University of Tarbiat Modares</primary_sponsor>
      <public_title>The effect of whole body vibration on patients with diabetic sarcopenia</public_title>
      <acronym></acronym>
      <scientific_title>Investigating the effect of whole body vibration on muscle mass, biomechanical parameters and metabolic factors in diabetic patients with sarcopenia</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2024-01-20</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>60</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/74017</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: Randomization in this study will be done by block randomization method. Participants will be randomly assigned into intervention or control groups. The size of blocks will be 4. Also, the blocks will be randomly placed in the envelopes. For random assignment, code 1 denotes the intervention group and code 0 denotes the control group in the envelopes. Subjects will choose an envelope and then, based on the chosen code, they are assigned to one of the groups.</study_design>
      <phase>N/A</phase>
      <hc_freetext>Condition 1: Sarcopenia. Condition 2: Type 2 diabetes.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: The intervention consists of 12 weeks of whole body vibration for individuals with diabetic sarcopenia. In the first session, after registering the basic information and getting familiar with how to perform the tests, the subjects will perform biomechanical and blood tests and then the variables will be recorded. In the next sessions, people should perform 3 times a week for 12 weeks, 5 to 12 vibration sets each with 60 seconds of vibration and 30 seconds of rest. After the end of 12 weeks, the final assessment session will be done in the laboratory like the first session. If subjects complete 80% of the sessions, which includes at least 30 treatment sessions, they will be included in the statistical analysis. Intervention 2: Control group: This group will not receive any vibration and the subjects will be evaluated before and after 12 weeks. In the first session, after registering the basic information and getting familiar with how to perform the tests, the subject will perform biomechanical and blood tests and then the variables will be recorded. After the end of 12 weeks, the final assessment session will be done in the laboratory like the first session.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
Information about the main outcome can be shared when the subjects be made unidentifiable.

When:
The access phase starts six months after the results publication

To whom:
Researchers in academic and research organizations will have access to the data.

Conditions:
To do scientific research

Where to obtain:
Sahar Boozari, Adress: Tarbiat Modares University; Jalal Al Ahmad Highway; Email: s.boozari@modares.ac.ir; Phone number: 00982182885053

How to obtain:
After sending the project plan and a complete evaluation of the persons and organizations involved in the project, the data will be sent following the approval.

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Motahare  Ababaf Behbahani</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Tarbiat Modares University, Nasr Bridge, Jalal Al ahmad Highway</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1411713116</zip>
        <telephone>+98 21 8288 5053</telephone>
        <email>m.behbahani@modares.ac.ir</email>
        <affiliation>The University of Tarbiat Modares</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Sahar Boozari</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Tarbiat Modares University, Nasr Bridge, Jalal Al ahmad Highway</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1411713116</zip>
        <telephone>+98 21 8288 5053</telephone>
        <email>s.boozari@modares.ac.ir</email>
        <affiliation>Tarbiat Modares University</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>At least 6 months history of diabetes
Diagnosis of sarcopenia in people with diabetes
Score less than 13 on Michigan Neuropathy Screening Instrument</inclusion_criteria>
      <agemin>60 years</agemin>
      <agemax>80 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Having thyroid disorders
GFR score above 30
History of acute ischemia such as infarction in less than 3 months
History of falling in the past year
Taking drugs and supplements that have known effects on the neuromuscular system (such as corticosteroids)</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>M62.84</hc_code>
      <hc_code>E11</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Sarcopenia</hc_keyword>
      <hc_keyword>Type 2 diabetes mellitus</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Other</i_code>
      <i_code>Other</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: The intervention consists of 12 weeks of whole body vibration for individuals with diabetic sarcopenia. In the first session, after registering the basic information and getting familiar with how to perform the tests, the subjects will perform biomechanical and blood tests and then the variables will be recorded. In the next sessions, people should perform 3 times a week for 12 weeks, 5 to 12 vibration sets each with 60 seconds of vibration and 30 seconds of rest. After the end of 12 weeks, the final assessment session will be done in the laboratory like the first session. If subjects complete 80% of the sessions, which includes at least 30 treatment sessions, they will be included in the statistical analysis.</i_keyword>
      <i_keyword>Control group: This group will not receive any vibration and the subjects will be evaluated before and after 12 weeks. In the first session, after registering the basic information and getting familiar with how to perform the tests, the subject will perform biomechanical and blood tests and then the variables will be recorded. After the end of 12 weeks, the final assessment session will be done in the laboratory like the first session.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Ground Reaction Force Parameters. Timepoint: Before and after 12 weeks of intervention. Method of measurement: Force plate device.</prim_outcome>
      <prim_outcome>Quality of Life Index. Timepoint: Before and after 12 weeks of interventions. Method of measurement: SarQoL questionnaire.</prim_outcome>
      <prim_outcome>Parameters of the  body  sway. Timepoint: قبل و بعد از 12 هفته مداخله. Method of measurement: Force plate.</prim_outcome>
      <prim_outcome>Body mass parameters. Timepoint: قبل و بعد از 12 هفته مداخله. Method of measurement: DXA.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Muscle strength. Timepoint: Before and after 12 weeks of intervention. Method of measurement: Dynamometer.</sec_outcome>
      <sec_outcome>Lipid profile. Timepoint: Before and after 12 weeks of intervention. Method of measurement: Blood test.</sec_outcome>
      <sec_outcome>Fasting blood sugar(FBS). Timepoint: Before and after 12 weeks of intervention. Method of measurement: Blood test.</sec_outcome>
      <sec_outcome>Glycated hemoglobin (A1C). Timepoint: Before and after 12 weeks of intervention. Method of measurement: Blood test.</sec_outcome>
      <sec_outcome>Inflammation factors. Timepoint: Before and after 12 weeks of intervention. Method of measurement: Blood test.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name>Research Institute of Endocrinology and Metabolism, Tehran Faculty of Medical Sciences</sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>University of Tarbiat Modares</source_name>
      <source_name>Research Institute of Endocrinology and Metabolism, Tehran Faculty of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2023-11-26</approval_date>
        <contact_name>Ethics committee of Tarbiat Modares University</contact_name>
        <contact_address>Tarbiat Modares University, Nasr Bridge, Jalal Al Ahmad Highway Tehran Tehran Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
